Morphology of TAT-μUtr-injected muscle. by Kevin J. Sonnemann (239809)

“…TAT-utrophin treatment led to a significant decrease in CNFs (54%±5% versus 37%±4%; PBS versus TAT; <i>n</i> = 3 PBS muscles; <i>n</i> = 4 TAT-μUtr muscles). * <i>p</i> = 0.04 (Student's <i>t</i> test). …”

Table_6_The in vivo dsRNA Cleavage Has Sequence Preference in Insects.pdf by Ruobing Guan (6063893)

“…We injected 0.04 mg/g dsRNA into Asian corn borers or cotton bollworms according to their body weight, and then the siRNAs produced in vivo were analyzed by RNA-Seq. We discovered that a large number of siRNAs were produced with GGU nucleotide residues at the 5′- and 3′-ends and produced a siRNA peak on the sequence. …”

Stabilization of neuronal injury in SIV-infected animals following natalizumab treatment. by Jennifer H. Campbell (353635)

“…Decreased NAA/Cr stabilized with natalizumab treatment (indicated by arrows at 28, 35, and 42 dpi) in the FC (E), PC (F), BG (G), and WM (<b>H</b>). …”

Image_1_Effects of Cardiomyocyte-Specific Deletion of STAT3–A Murine Model of Heart Failure With Preserved Ejection Fraction.TIF by Weilin Zhao (766615)

“…Other indicators reflecting cardiac passive stiffness and diastolic function, including end diastolic pressure volume relation, MV A value, MV E value, E/A and E/E' had different fold changes. …”

Image_2_Effects of Cardiomyocyte-Specific Deletion of STAT3–A Murine Model of Heart Failure With Preserved Ejection Fraction.TIF by Weilin Zhao (766615)

“…Other indicators reflecting cardiac passive stiffness and diastolic function, including end diastolic pressure volume relation, MV A value, MV E value, E/A and E/E' had different fold changes. …”

Mechanical and microstructure characterization of hard nanostructured N-bearing thin coating by Cabibbo, M.

“…The main problem with steel, is that it exhibits a relatively low hardness (below 10GPa) which strongly decreases upon annealing above about 600K. …”
Get full text

Epidemiology of herpes simplex virus type 2 in Europe: systematic review, meta-analyses, and meta-regressions by Alareeki, Asalah

“…Seroprevalence decreased by 1% per calendar year. Pooled mean proportions of HSV-2 detection in GUD and in genital herpes were 22.0% (95% CI: 15.3–29.6%) and 66.0% (95% CI: 62.9–69.1%), respectively. …”
Get full text
Get full text
Get full text

Table_1_Peripheral Blood Biomarkers for Early Diagnosis, Severity, and Prognosis of Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer.docx by Xinqing Lin (9659243)

“…Background<p>Checkpoint inhibitor-related pneumonitis (CIP) is a potentially fatal immune-related adverse event that occurs during treatment with immune checkpoint inhibitors (ICIs). …”

Image_6_Epidemiological and demographic drivers of lung cancer mortality from 1990 to 2019: results from the global burden of disease study 2019.tif by Yaguang Fan (15415049)

“…Decomposition analysis was used to analyze the contributions of epidemiological and demographic drivers to lung cancer mortality.</p>Results<p>Despite a non-significant decrease in ASMR [EAPC = −0.31, 95% confidence interval (CI): −1.1 to 0.49], the number of deaths from lung cancer increased by 91.8% [95% uncertainty interval (UI): 74.5–109.0%] between 1990 and 2019. …”

DataSheet_1_Peripheral Blood Biomarkers for Early Diagnosis, Severity, and Prognosis of Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer.xlsx by Xinqing Lin (9659243)

“…Background<p>Checkpoint inhibitor-related pneumonitis (CIP) is a potentially fatal immune-related adverse event that occurs during treatment with immune checkpoint inhibitors (ICIs). …”

Table_1_Epidemiological and demographic drivers of lung cancer mortality from 1990 to 2019: results from the global burden of disease study 2019.doc by Yaguang Fan (15415049)

“…Decomposition analysis was used to analyze the contributions of epidemiological and demographic drivers to lung cancer mortality.</p>Results<p>Despite a non-significant decrease in ASMR [EAPC = −0.31, 95% confidence interval (CI): −1.1 to 0.49], the number of deaths from lung cancer increased by 91.8% [95% uncertainty interval (UI): 74.5–109.0%] between 1990 and 2019. …”

Image_3_Epidemiological and demographic drivers of lung cancer mortality from 1990 to 2019: results from the global burden of disease study 2019.tif by Yaguang Fan (15415049)

“…Decomposition analysis was used to analyze the contributions of epidemiological and demographic drivers to lung cancer mortality.</p>Results<p>Despite a non-significant decrease in ASMR [EAPC = −0.31, 95% confidence interval (CI): −1.1 to 0.49], the number of deaths from lung cancer increased by 91.8% [95% uncertainty interval (UI): 74.5–109.0%] between 1990 and 2019. …”

Data_Sheet_1_Epidemiological and demographic drivers of lung cancer mortality from 1990 to 2019: results from the global burden of disease study 2019.docx by Yaguang Fan (15415049)

“…Decomposition analysis was used to analyze the contributions of epidemiological and demographic drivers to lung cancer mortality.</p>Results<p>Despite a non-significant decrease in ASMR [EAPC = −0.31, 95% confidence interval (CI): −1.1 to 0.49], the number of deaths from lung cancer increased by 91.8% [95% uncertainty interval (UI): 74.5–109.0%] between 1990 and 2019. …”

Image_4_Epidemiological and demographic drivers of lung cancer mortality from 1990 to 2019: results from the global burden of disease study 2019.tif by Yaguang Fan (15415049)

“…Decomposition analysis was used to analyze the contributions of epidemiological and demographic drivers to lung cancer mortality.</p>Results<p>Despite a non-significant decrease in ASMR [EAPC = −0.31, 95% confidence interval (CI): −1.1 to 0.49], the number of deaths from lung cancer increased by 91.8% [95% uncertainty interval (UI): 74.5–109.0%] between 1990 and 2019. …”

Image_2_Epidemiological and demographic drivers of lung cancer mortality from 1990 to 2019: results from the global burden of disease study 2019.tif by Yaguang Fan (15415049)

“…Decomposition analysis was used to analyze the contributions of epidemiological and demographic drivers to lung cancer mortality.</p>Results<p>Despite a non-significant decrease in ASMR [EAPC = −0.31, 95% confidence interval (CI): −1.1 to 0.49], the number of deaths from lung cancer increased by 91.8% [95% uncertainty interval (UI): 74.5–109.0%] between 1990 and 2019. …”

Image_1_Epidemiological and demographic drivers of lung cancer mortality from 1990 to 2019: results from the global burden of disease study 2019.tif by Yaguang Fan (15415049)

“…Decomposition analysis was used to analyze the contributions of epidemiological and demographic drivers to lung cancer mortality.</p>Results<p>Despite a non-significant decrease in ASMR [EAPC = −0.31, 95% confidence interval (CI): −1.1 to 0.49], the number of deaths from lung cancer increased by 91.8% [95% uncertainty interval (UI): 74.5–109.0%] between 1990 and 2019. …”

Tau knockout prevents sensitivity to Kainic acid–mediated stress in AICD-Tg mice. by Kaushik Ghosal (244754)

“…C. Mean seizure severity scores showed a significant rescue of seizure severity by Tau-/- in AICD animals. n = 4–5 mice per group (A-C). …”

Thirty-year Trends in Complications in U.S. Adults With Newly Diagnosed Type 2 Diabetes by Michael Fang (9708234)

“…</p> <p><b>Results: </b>From 1988-1994 to 2011-2018, there was a significant decrease in the prevalence of albuminuria (38.9 to 18.7%, p-for-trend<0.001), but no change in the prevalence of reduced eGFR (7.5 to 9.9%, p-for-trend=0.30), retinopathy (1988-1994 to 1999-2008 only; 13.2 to 12.1%, p-for-trend=0.86), or self-reported cardiovascular disease (19.0 to 16.5%, p-for-trend=0.64). …”

Expression of Sox2, Sox10, Gata3, Prox1 and Peripherin during primary auditory neuron development and maturation. by Koji Nishimura (2077804)

“…At E10.5, Sox10 was downregulated as neuroblasts delaminated from the otocyst. …”

Evaluation of emerging NASH therapies: the impact of treatment efficacy profiles on long-term health outcomes: Supplementary materials by William L Herring (14039541)

“…The fibrosis worsening profile reduced predicted 10-year LRC rates (F1:</p> <p>1.9%; F2: 6.5%; F3: 19.1%; F4/CC: 55.0%) more than the resolution and fibrosis improvement profiles</p> <p>(F1: 2.6%/2.6%; F2: 8.5%/8.3%; F3: 23.3%/23.0%; F4/CC: NA/59.0%). …”